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Abstract
Objectives Bleeding after tooth extraction range from minor bleeding to life-threating haemorrhagic shock and are among the
leading complications in patients under oral anticoagulation with direct oral anticoagulants (DOACs) or phenprocoumon. Little is
known about how anticoagulation in patients under DOAC or phenprocoumon alters the characteristics, treatment or outcome of
bleeding events, in comparison to non-anticoagulated patients.
Methods Patients admitted to a tertiary ED in Bern, Switzerland, from June 1st 2012 to 31st May 2016 with bleeding related to
tooth extraction under DOAC, phenprocoumon or without anticoagulation, were compared.
Results Out of 161,458 emergency consultations, 64 patients with bleeding from tooth extraction were included in our study. In
anticoagulation groups, we found significantly more delayed bleeding events than in patients without anticoagulation (9 (81.3%)
DOAC, 19 (86.4%) phenprocoumon, 8 (30.8%) no anticoagulation, p < 0.001). Anticoagulated patients had to stay longer in the
ED than non-anticoagulated patients, with no significant difference between DOAC or phenprocoumon (hours: 4.8 (3.2–7.6
IQR) DOAC, 3.0 (2.0–5.5 IQR) phenprocoumon, p = 0.133; 2.7 (1.6–4.6) no anticoagulation; p = 0.039). More patients with
anticoagulation therapy needed surgery than patients without anticoagulant therapy (11 (68.8%) DOAC, 12 (54.6%) VKA, p =
0.506; 7(26.9%) no anticoagulation; p = 0.020).
Conclusions Delayed bleeding occur more often in anticoagulated patients with both DOAC and phenprocoumon compared to
patients without anticoagulation. Bleeding events in anticoagulated patients with DOAC and phenprocoumon equally need
longer ED treatment and more frequent surgical intervention.
Clinical relevance Caution with delayed bleeding in anticoagulated patients with DOACs and phenprocoumon is necessary and
treatment of bleeding is resource-demanding.
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Abbreviations
DOAC Direct oral anticoagulant
ED Emergency department
VKA Vitamin K antagonist
Introduction
Bleeding events are one of the leading complications after
tooth extraction, with an incidence of up to 25%. These
range from frequent minor bleeding to rare life-threating
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haemorrhagic shock, even in healthy patients [1]. Previous
studies have found no significant difference in bleeding inci-
dence between patients on oral anticoagulant therapy with the
vitamin K antagonist (VKA) warfarin than with patients with-
out anticoagulant medication [2, 3]. In analogy to vitamin K
antagonists, guidelines on the management of anticoagulants
and tooth extraction therefore recommend that direct oral
anticoagulant (DOAC) therapy should be continued in
most dental procedures [4].
Most bleeding events from tooth extraction under
anticoagulation may be stoppable within the outpatient set-
ting. However, major bleeding complications can lead to ad-
mission to the emergency department (ED). This is becoming
increasingly common with the growth in the use of DOACs
[5]. While treatment guidelines about the perioperative man-
agement of rivaroxaban exist [3], a recent literature review of
DOACs and tooth extraction found only limited evidence on
the effects of DOACs on postoperative bleeding after extrac-
tion. A lack of evidence-based work on the management of
bleeding events was identified [3].
The aim of the study was therefore to compare patient groups
with oral anticoagulation with DOAC and phenprocoumon with
patients without oral anticoagulation, with respect to the charac-
teristics of bleeding, treatment and outcome.
Methods
The study population for this retrospective study included all
admissions between June 1st 2012 and 31st May 2016 to the
adult tertiary ED of Inselspital, Bern University Hospital. This
department treats about 40,000 emergency patients per year and
has a catchment area of about 2 million people in Canton Bern,
Switzerland [6]. The study hospital provides a 24/7 service
from the department of cranio-maxillofacial surgery and is the
only cranio-maxillofacial centre in the catchment area.
All patients who consulted us with bleeding from tooth
extraction, taking one of the approved anticoagulants,
DOAC or phenprocoumon on arrival at our ED, were includ-
ed. They were compared with patients who were not on oral
anticoagulant therapy (see Fig. 1).
In order to identify all patients admitted with bleeding from
tooth extraction, a keyword search for Btooth^/Bteeth^ and
Bbleeding^/Bhematoma^ with different semantic combina-
tions was performed in the medical records of all patients
admitted in the study period. In our ED, diagnoses and proce-
dures are documented in free text. Because ICD or OPCS
codes in our department are generated only afterwards for
billing purposes, free text reflects the medical conditions and
necessities more closely and free of economic considerations.
Patients without bleeding from tooth extraction were excluded
by independent full-text assessment of the medical records by
two researchers (MM and TS). Included patients were
grouped by their anticoagulation status on arrival (DOAC,
phrenprocoumon, no anticoagulation). All in Switzerland ap-
proved DOAC were included in our search [7]. Rivaroxaban
is the most commonly prescribed of DOAC in Switzerland
and our ED population [5]. Phenprocoumon is the most com-
monly used vitamin K antagonist, both in our patient popula-
tion as well as in the rest of continental Europe and was there-
fore employed for comparison as a vitamin K antagonist [8].
To compare patient and bleeding characteristics, we ex-
tracted clinical and demographic data, including gender, age,
the indication for anticoagulant therapy, as well as the time
point of bleeding after extraction and the number and location
of extracted teeth.
Furthermore, the impact and treatment of bleeding from
tooth extraction was evaluated by extracting information on




- gall stone and 
kidney stone 
extractions
Patients identified through key-word search 
“tooth extraction” / “extraction” / ”extract” AND “bleeding” / ”haematoma”
in all medical reports from June 1st 2012 – 31st May 2016
(n = 708)
Tooth extraction-related bleeding included (n= 64):
- Rivaroxaban (n = 12)
- Apixaban (n = 4)
- Phenprocoumon (n= 21)
- No oral anticoagulant (n= 27)
Fig. 1 Flowchart
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the haemoglobin level on admission, the presence of anaemia
(defined as less than 120 g/l for adult (> 15 years) non-
pregnant woman and less than 130 g/l for adult men, accord-
ing to the World Health Organisation [9], the need and extent
of blood transfusion, the extent of local anaesthesia and the
need for medical and surgical intervention. Bleeding in the
first 24 h after tooth extraction was considered as early bleed-
ing, > 24 h after extraction as delayed bleeding—as defined by
Miclotte et al. [10].
The outcome of bleeding was assessed by the need for
hospital admission as well as length of hospital and ED stay.
Statistics
We used Stata® 13.1 (StataCorp, The College Station, Texas,
USA) for statistical analysis. The distribution of age, time
spent on ED and length of hospital stay within the three dif-
ferent anticoagulation groups (DOAC, phenprocoumon and
no anticoagulation) were presented as medians with 25th–
75th interquartile ranges (IQR). The Mann-Whitney U test
or the Kruskal-Wallis test were used to compare the distribu-
tion of these variables between patients taking DOAC vs.
phenprocoumon and between all three anticoagulation groups.
Categorical variables are presented as frequency (proportion).
Fisher’s exact test was performed to test for an association
between a categorical variable, e.g. hospitalisation rate, and
anticoagulation group over all three categories as well as only
between the DOAC vs. phenprocoumon group. A p value of
< 0.05 was considered significant.
Ethical considerations
This study was registered and approved by the Ethics
Committee of the Canton of Bern, Switzerland (073/2015).
Individual informed consent was waived because of the retro-
spective design and anonymised analysis of data.
Results
The database comprised 161,458 consultations in the ED of
Bern University Hospital, Switzerland, from June 1st 2012 to
31st May 2016. The keyword search for Btooth^ /Bteeth^
AND Bbleeding^/Bhematoma^ identified 708 patients. Of
these patients, 644 were excluded as they exhibited dental
pathologies that were unrelated to extraction, prior bleeding
events or other non-dental extractions. In total, 64 patients
were included with bleeding events related to tooth extraction.
For further group comparison, 16 patients with DOAC (12
patients with rivaroxaban and 4 with apixaban), 21 patients
with phenprocoumon and 27 patients without oral anticoagu-
lant medication were included (Fig. 1).
An overview of baseline characteristics of patient
groups with DOAC, phenprocoumon and without antico-
agulant medication is presented in Table 1. All three pa-
tient groups were comparable with respect to gender (male:
7 (43.8%) DOAC vs. 13 (59.1%) VKA vs. 15 (57.7%) no
anticoagulation; p = 0.657) as well as in the number of
teeth extracted (single tooth: 15 (93.8%) DOAC vs. 19
(86.4%) VKA vs. 20 (76.9%) no anticoagulation; p =
0.343) and region of extraction. For details about the re-
gion of bleeding, see Table 1. In seven patients, the docu-
mented underlying procedure of the bleeding was an
osteotomy (DOAC n = 1 vs. phenprocoumon n = 1 vs. no
anticoagulation n = 5, p = 0.351). In all other patients, only
tooth extractions were documented. Twelve (50.0%) pa-
tients without anticoagulant medication had third molar
removal in contrast to no patients on rivaroxaban and two
(10.0%) patients on vitamin K antagonist with third molar
removal (p < 0.001). There was no significant difference in
age between the DOAC and phenprocoumon group
(76 years (IQR 73–83) vs. 76 years (IQR 67–82); p =
0.478); however, the patient groups on anticoagulation
were significantly older than the patients without
anticoagulation (77 vs. 44 years).
The time point of the bleeding events was examined and
no difference between the phenprocoumon and DOAC
groups was found with respect to the incidence of delayed
bleeding (9 (81.3%) vs. 19 (86.4%), respectively; p =
0.624). In contrast to this, both these treatment groups ex-
hibited significantly more delayed bleeding events than the
group without anticoagulation (no anticoagulation: 8
(30.8%) delayed bleeding; p < 0.001). All characteristics
of bleeding events for the different groups are summarised
in Table 1.
We found no significant differences between the groups
with respect to the impact of the bleeding events (anaemia
on admission (7 (43.8%) DOAC, 6 (28.6%) VKA, 4
(15.4%) no anticoagulation; p = 0.375), the need for blood
transfusion (1 (6.3%) DOAC, 0 VKA, 1 (3.9%) no
anticoagulation; p = 0.716).
Regarding outcome of the bleeding events, it was found
that patients on either therapy with DOAC or phenprocoumon
had to stay longer in the ED than non-anticoagulated patients,
with no significant difference between DOAC or
phenprocoumon (hours: 4.8 (3.2–7.6 IQR) DOAC, 3.0 (2.0–
5.5 IQR) VKA, 2.7 (1.6–4.6) no anticoagulation; p = 0.039,
Table 2). There were no significant differences (8 patients
(50%) DOAC, 9 patients (40.9%) VKA, 7 (26.9%) no
anticoagulation; p = 0.310)) in the length of hospital stay
(days: 1 (1–2 IQR) for DOAC and VKA vs. 3 (1–6 IQR) no
anticoagulation; p = 0.370) (Table 2).
In regard to the therapeutic management of the bleeding
events, significantly more patients with anticoagulation thera-
py needed surgery than did patients without anticoagulant
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therapy (11 (68.8%) DOAC, 12 (54.6%) VKA, 7 (26.9%)
no anticoagulation; p = 0.020). These patients also tended
to spend more time in the ED. No difference could be
demonstrated between the DOAC and VKA groups.
There was no significant difference between the groups
with respect to the options for conservative treatment
(see Table 2).
Discussion
In summary, patients on anticoagulant therapy had more de-
layed bleeding events and were more likely to require surgery
than patients not on anticoagulants and had to spend more
time in the ED. No differences were found between different
anticoagulants.
Table 2 The impact of tooth extraction related bleeding in different patient groups taking DOAC (n = 16; rivaroxaban, n = 12 and abixaban, n = 4),
phenprocoumon (n = 22), and no anticoagulant medication (n = 26), Mann-Whitney U test, Kruskal-Wallis test or Fisher’s exact test, as applicable
DOAC Phenprocoumon p (D. vs. P.) No anticoagulant p (all)
Anaemia, (n (%)) 7 (43.8) 6 (28.6) 4 (15.4)
Not specified 5 (31.3) 7 (31.8) 0.508 10 (38.5) 0.375
Blood transfusion, (n (%)) 1 (6.25) 0 (0.0) 0.421 1 (3.9) 0.716
Surgery, (n (%)) 11 (68.8) 12 (54.6) 0.506 7 (26.9) 0.020
Conservative, (n (%))
No therapy needed 3 (60.0) 3 (30.0) 7 (36.8)
Gauze packing (GP) 2 (40.0) 5 (50.0) 10 (52.6)
Cauterisation + GP 0 (0.0) 2 (20.0) 0.615 2 (10.5) 0.806
ED stay, hour (median (IQR)) 4.8 (3.2–7.6) 3.0 (2.0–5.5) 0. 133 2.7 (1.6–4.6) 0.039
Hospital admissions, (n (%)) 8 (50.0) 9 (40.9) 0. 743 7 (26.9) 0.310
Length of hospital stay, days (median (IQR)) 1 (1–2) 1 (1–2) 1.000 3 (1–6) 0.370
Table 1 Comparison of study characteristics between teeth extraction
related bleeding in patients taking DOAC (n = 16; rivaroxaban, n = 12
and abixaban, n = 4), phenprocoumon (n = 22), and no anticoagulation
(n = 26), Mann-Whitney U test, Kruskal-Wallis test or Fisher’s exact
test, as applicable
DOAC Phenprocoumon p (D. vs. P.) No anticoagulation p (all)
Age, (median (IQR)) 76 (73–83) 76 (67–82) 0.478 44 (23–59) < 0.001
Male, (n (%)) 7 (43.8) 13 (59.1) 0.512 15 (57.7) 0. 657
Indication anticoagulation, (n (%))
Atrial fibrillation (AF) 9 (56.3) 9 (40.9)
Pulmonary embolism (PE) 1 (6.3) 0 (0)
AF + PE 4 (25.0) 0 (0)
Valve/vascular replacement 0 (0) 7 (31.8)
Not specified 2 (12.5) 6 (27.3) 0.004
Recurrent bleeding, (n (%)) 2 (12.5) 3 (13.6) 1.000 0 (0.0) 0.105
Extracted teeth, (n (%))
Single 15 (93.8) 19 (86.4) 20 (76.9)
Multi 1 (6.3) 3 (13.6) 0. 624 6 (23.1) 0.343
Region*, (n (%))
Lower jaw 2 (16.7) 10 (47.6) 10 (41.7)
Upper jaw 10 (83.3) 11 (52.4) 10 (41.7)
Both 0 (0.0) 0 (0) 0.133 4 (16.7) 0.052
Third molar extraction, (n (%)) 0 (0.0) 2 (10.0) 0.508 12 (50.0) <0.001
Time after extraction, (n (%))
Early bleeding 3 (18.8) 3 (13.6) 16 (61.5)
Delayed bleeding 9 (81.3) 19 (86.4) 8 (30.8)
Not specified 0 (0.0) 0 (0) 0.682 2 (7.7) <0.001
*If specified. AF atrial fibrillation, D. DOAC, P. phenprocoumon, PE pulmonary embolism
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The anticoagulant groups and non-anticoagulant group in
our study are comparable with respect to gender and number
as well as region of teeth extracted. The greater age of patients
with anticoagulant medication in comparison to patients with-
out anticoagulation may very well be explained by the greater
prevalence of atrial fibrillation in older patients [11]. This
greater age may warrant more caution in this patient group,
as fatal complications have been documented previously, par-
ticularly in the elderly [12]. As third molar removal is typical-
ly performed in young patients, the observed greater number
of third molar removal in patients without anticoagulation
compared to patients on any anticoagulation likely reflects
the higher age of patients on anticoagulant medication. With
our retrospective data, we cannot make a statement about the
general prevalence of third molar removal in our populations.
This should be topic of further research to better understand
the mechanisms of bleeding.
It is unclear whether there is an underlying pathophysiological
mechanism that explains the greater number of delayed bleeding
events in the two anticoagulant groups compared to patients
without anticoagulation. According to current guidelines, it is
not recommended that DOAC should be interrupted for minor
dental interventions [4]. Although the time point of last dose of
medication is not routinely documented in our medical database,
it is possible that the delayed bleeding may be connected with
restarting anticoagulant therapy. Unfortunately, for DOAC pa-
tients, concentrations of anticoagulant drugs, that may provide
insights into the mechanisms of bleeding events, were not rou-
tinely measured in our retrospective data. It might therefore be
desirable to measure DOAC levels in specific high-risk popula-
tions in the future. This finding of increased delayed bleeding
events may as well prompt the dentist or treating ED clinician to
be cautious with follow-up appointments in anticoagulated
patients. It is important that all physicians treating
anticoagulated patients are well informed about bleeding
complications and risk stratification of individual patients.
A recent systematic review attempted to identify evidence-
based interventions for treating post-extraction bleeding in pa-
tients without anticoagulants. The authors concluded that, due
the lack of Breliable evidence on this topic, clinicians must use
their clinical experience to determine the most appropriate means
of treating this condition^ [1]. Therefore, our standard procedure
for postoperative bleeding is mostly related to management rec-
ommendations for invasive dental treatment in patients using oral
antithrombotic medication [3, 10]. In patients with coagulopa-
thies, bleeding management is even more challenging, as the
clinical experience in treating such complications is smaller
[13, 14]. This more difficult treatment of anticoagulant related
bleeding is reflected in our data with an increased number of
patients taken to theatre with anticoagulant related tooth extrac-
tion bleeding compared to patients without anticoagulation. This
is similar for DOAC and classical anticoagulant therapy with
phenprocoumon and makes therapy in these patient groups more
expensive and demands more resources. This may develop into
an important issue with the increasing number of anticoagulated
patients, especially with DOACs [5]. Both DOAC and
phenprocoumon patients tended to stay for longer periods in
the ED than non-anticoagulated patients. This contributes to the
issue of costs andmaymake greater demands on the patient-flow
organisation at the treating ED. As regards outcome parameters,
there were no differences between the group with respect to the
number of hospital admissions and length of hospitalisation.
Real-life data, also including economical considerations
in connection with bleeding events, are emerging on
anticoagulation and the newer DOACs [15]. Those studies
may influence the choice of a specific anticoagulant med-
ication. However, based on the literature and our data, it is
not yet possible to make recommendations for a specific
anticoagulant therapy for dental bleeding.
Limitations
A limitation of this study is the selective design, with the
inclusion of ED patients presenting with a condition that is
often treated out of hospital. Nevertheless, we included major
bleeding related to tooth extraction that would have been po-
tentially harmful to the patient if not treated adequately. The
treatment of minor bleeding in the outpatient setting may ex-
plain the low number of cases admitted to our hospital. As the
sample is small, despite over 160,000 screened ED consulta-
tions, it is not possible to exclude that our study is underpow-
ered to detect a difference between the different anticoagulant
groups. The influence of the surgical technique on the impact
and outcome of bleeding was not analysed in this study. The
bleeding risk may be lower in the case of primary closure of
the extraction socket. As with all retrospective data, no guar-
antee can be given for the completeness of the medical docu-
mentation, as this was performed by the responsible treating
physician. In addition to this, the risk of missing patients in
retrospective database research can only beminimised, but not
excluded, as we did with two independent raters responsible
for the inclusion of patients and full-text database screening.
Conclusion
Our study suggests that delayed bleeding events after tooth
extraction occur more often in anticoagulated patients than in
patients without oral anticoagulant therapy, but no difference
between DOAC and phenprocoumon could be demonstrated.
In addition to this, bleeding in patients on anticoagulants re-
quired surgery more often and more protracted ED treatment
was necessary compared to patients without anticoagulation.
Due to the low incidence, future research is recommended to
confirm our findings in larger populations and find possible
differences between different types of oral anticoagulation.
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